(JAZZ) Jazz Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 14.497m USD | Total Return: 115.7% in 12m

Sleep Medicine, Oncology, Cannabinoids, Rare Diseases
Total Rating 61
Safety 73
Buy Signal 1.38
Biotechnology
Industry Rotation: -4.3
Market Cap: 14.5B
Avg Turnover: 197M
Risk 3d forecast
Volatility29.3%
VaR 5th Pctl4.76%
VaR vs Median-1.35%
Reward TTM
Sharpe Ratio2.16
Rel. Str. IBD91.1
Rel. Str. Peer Group80.1
Character TTM
Beta0.489
Beta Downside-0.041
Hurst Exponent0.533
Drawdowns 3y
Max DD32.71%
CAGR/Max DD0.60
CAGR/Mean DD1.38
EPS (Earnings per Share) EPS (Earnings per Share) of JAZZ over the last years for every Quarter: "2021-03": 3.92, "2021-06": 3.9, "2021-09": 4.2, "2021-12": 4.21, "2022-03": 3.73, "2022-06": 4.3, "2022-09": 5.17, "2022-12": -0.07, "2023-03": 3.95, "2023-06": 4.51, "2023-09": 4.84, "2023-12": 5.02, "2024-03": 2.68, "2024-06": 5.3, "2024-09": 6.61, "2024-12": 6.6, "2025-03": -1.52, "2025-06": -8.25, "2025-09": 8.13, "2025-12": 6.64, "2026-03": 6.34,
EPS CAGR: 10.91%
EPS Trend: -10.7%
Last SUE: 0.64
Qual. Beats: 0
Revenue Revenue of JAZZ over the last years for every Quarter: 2021-03: 607.581, 2021-06: 751.811, 2021-09: 838.115, 2021-12: 896.731, 2022-03: 813.721, 2022-06: 932.878, 2022-09: 940.652, 2022-12: 972.123, 2023-03: 892.812, 2023-06: 957.317, 2023-09: 972.14, 2023-12: 1011.935, 2024-03: 901.983, 2024-06: 1023.825, 2024-09: 1054.969, 2024-12: 1088.173, 2025-03: 897.841, 2025-06: 1045.712, 2025-09: 1126.107, 2025-12: 1197.926, 2026-03: 1068.9,
Rev. CAGR: 3.70%
Rev. Trend: 69.8%
Last SUE: 2.38
Qual. Beats: 1

Warnings

High Debt/EBITDA (9.0) with thin interest coverage (-0.8)

Interest Coverage Ratio -0.8 is critical

Tailwinds

Supp Ema8, Supp Ema20, Leader, Tailwind

Description: JAZZ Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC is a global biopharmaceutical company specializing in the development and commercialization of treatments for neuroscience and oncology. Its primary portfolio includes Xywav for sleep disorders, Epidiolex for rare seizure syndromes, and several specialized therapies for hematologic malignancies and solid tumors, such as Rylaze and Zepzelca.

The company operates within the specialty pharmaceutical sector, where business models often focus on orphan drug designations to secure extended market exclusivity and premium pricing for rare disease treatments. Jazz manages a robust pipeline of candidates in various clinical stages, including Zanidatamab for HER2-positive cancers and various molecules targeting Raf and Ras mutant tumors.

Strategic growth is supported by licensing and collaboration agreements with international partners like Zymeworks and Sumitomo Pharma. Investors investigating the companys long-term valuation metrics may find further insights on ValueRay. Founded in 2003 and headquartered in Dublin, Ireland, the firm maintains a presence across the United States and Europe.

Headlines to Watch Out For
  • Xywav adoption and transition from Xyrem drive long-term oxyate franchise stability
  • Epidiolex sales growth in pediatric epilepsy markets sustains neuroscience revenue momentum
  • Zanidatamab clinical trial results and regulatory approvals determine future oncology valuation
  • Generic competition for high-margin sleep medications threatens core cash flow generation
  • Expansion of Rylaze and Zepzelca portfolios mitigates reliance on legacy sleep products
Piotroski VR‑10 (Strict) 3.5
Net Income: 29.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA -2.40 > 1.0
NWC/Revenue: 52.64% < 20% (prev 71.47%; Δ -18.83% < -1%)
CFO/TA 0.11 > 3% & CFO 1.33b > Net Income 29.5m
Net Debt (3.57b) to EBITDA (395.4m): 9.03 < 3
Current Ratio: 2.04 > 1.5 & < 3
Outstanding Shares: last quarter (66.1m) vs 12m ago 8.40% < -2%
Gross Margin: 84.12% > 18% (prev 0.89%; Δ 8.32k% > 0.5%)
Asset Turnover: 37.95% > 50% (prev 35.24%; Δ 2.71% > 0%)
Interest Coverage Ratio: -0.80 > 6 (EBITDA TTM 395.4m / Interest Expense TTM 204.6m)
Altman Z'' 1.50
A: 0.20 (Total Current Assets 4.58b - Total Current Liabilities 2.25b) / Total Assets 11.86b
B: 0.08 (Retained Earnings 939.2m / Total Assets 11.86b)
C: -0.01 (EBIT TTM -163.1m / Avg Total Assets 11.70b)
D: 0.04 (Book Value of Equity 288.3m / Total Liabilities 7.33b)
Altman-Z'' Score: 1.50 = BB
Beneish M -2.91
DSRI: 1.17 (Receivables 836.3m/653.0m, Revenue 4.44b/4.06b)
GMI: 1.06 (GM 84.12% / 88.81%)
AQI: 0.95 (AQ_t 0.59 / AQ_t-1 0.62)
SGI: 1.09 (Revenue 4.44b / 4.06b)
TATA: -0.11 (NI 29.5m - CFO 1.33b) / TA 11.86b)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of JAZZ shares? As of May 16, 2026, the stock is trading at USD 228.77 with a total of 1,345,354 shares traded.
Over the past week, the price has changed by +1.32%, over one month by +14.77%, over three months by +36.19% and over the past year by +115.68%.
Is JAZZ a buy, sell or hold? Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.
  • StrongBuy: 10
  • Buy: 6
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the JAZZ price?
Analysts Target Price 241.8 5.7%
Jazz Pharmaceuticals (JAZZ) - Fundamental Data Overview as of 16 May 2026
P/E Trailing = 1925.4167
P/E Forward = 12.3153
P/S = 3.266
P/B = 3.1257
P/EG = 0.9406
Revenue TTM = 4.44b USD
EBIT TTM = -163.1m USD
EBITDA TTM = 395.4m USD
Long Term Debt = 4.32b USD (from longTermDebt, last quarter)
Short Term Debt = 1.05b USD (from shortTermDebt, last quarter)
Debt = 5.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.57b USD (from netDebt column, last quarter)
Enterprise Value = 17.04b USD (14.50b + Debt 5.42b - CCE 2.87b)
Interest Coverage Ratio = -0.80 (Ebit TTM -163.1m / Interest Expense TTM 204.6m)
EV/FCF = 13.68x (Enterprise Value 17.04b / FCF TTM 1.25b)
FCF Yield = 7.31% (FCF TTM 1.25b / Enterprise Value 17.04b)
FCF Margin = 28.06% (FCF TTM 1.25b / Revenue TTM 4.44b)
Net Margin = 0.66% (Net Income TTM 29.5m / Revenue TTM 4.44b)
Gross Margin = 84.12% ((Revenue TTM 4.44b - Cost of Revenue TTM 705.1m) / Revenue TTM)
Gross Margin QoQ = 71.34% (prev none%)
Tobins Q-Ratio = 1.44 (Enterprise Value 17.04b / Total Assets 11.86b)
Interest Expense / Debt = 1.17% (Interest Expense 63.3m / Debt 5.42b)
Taxrate = 2.04% (6.10m / 299.2m)
NOPAT = -159.8m (EBIT -163.1m * (1 - 2.04%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 4.58b / Total Current Liabilities 2.25b)
Debt / Equity = 1.20 (Debt 5.42b / totalStockholderEquity, last quarter 4.53b)
Debt / EBITDA = 9.03 (Net Debt 3.57b / EBITDA 395.4m)
Debt / FCF = 2.87 (Net Debt 3.57b / FCF TTM 1.25b)
Total Stockholder Equity = 4.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.25% (Net Income 29.5m / Total Assets 11.86b)
RoE = 0.71% (Net Income TTM 29.5m / Total Stockholder Equity 4.13b)
RoCE = -1.93% (EBIT -163.1m / Capital Employed (Equity 4.13b + L.T.Debt 4.32b))
 RoIC = -1.68% (negative operating profit) (NOPAT -159.8m / Invested Capital 9.49b)
 WACC = 5.92% (E(14.50b)/V(19.91b) * Re(7.70%) + D(5.42b)/V(19.91b) * Rd(1.17%) * (1-Tc(0.02)))
Discount Rate = 7.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 3.67%
[DCF] Terminal Value 87.32% ; FCFF base≈1.34b ; Y1≈1.49b ; Y5≈1.95b
[DCF] Fair Price = 858.1 (EV 57.41b - Net Debt 3.57b = Equity 53.84b / Shares 62.7m; r=6.0% [WACC]; 5y FCF grow 12.81% → 3.0% )
EPS Correlation: -10.74 | EPS CAGR: 10.91% | SUE: 0.64 | # QB: 0
Revenue Correlation: 69.81 | Revenue CAGR: 3.70% | SUE: 2.38 | # QB: 1
EPS current Quarter (2026-06-30): EPS=6.12 | Chg30d=+2.41% | Revisions=+25% | Analysts=15
EPS next Quarter (2026-09-30): EPS=6.34 | Chg30d=+0.73% | Revisions=-12% | Analysts=15
EPS current Year (2026-12-31): EPS=25.32 | Chg30d=+5.61% | Revisions=+50% | GrowthEPS=+202.1% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=25.51 | Chg30d=+2.01% | Revisions=+41% | GrowthEPS=+0.8% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: +50%